AVI BioPharma, Inc. (AVII) Reports Solid Q4 Results; Guides FY12
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
General and administrative: 22.18M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
General and administrative: 22.18M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q4 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.03 million.
Sees FY2012 revenue of $40-$50 million, versus the consensus of $54.14 million. Sees a loss from operations of $30-$35 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Sees FY2012 revenue of $40-$50 million, versus the consensus of $54.14 million. Sees a loss from operations of $30-$35 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Sandisk targets mid-to-high teens revenue growth through FY2030
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
